Lantern Pharma Inc.
LTRN
$3.59
-$0.03-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.80% | -7.77% | -11.98% | -6.92% | 2.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.27% | 25.98% | 26.50% | 31.88% | 23.87% |
| Operating Income | -24.27% | -25.98% | -26.50% | -31.88% | -23.87% |
| Income Before Tax | -30.19% | -25.96% | -24.46% | -25.19% | -11.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.19% | -25.96% | -24.46% | -25.19% | -11.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.19% | -25.96% | -24.46% | -25.19% | -11.93% |
| EBIT | -24.27% | -25.98% | -26.50% | -31.88% | -23.87% |
| EBITDA | -24.27% | -25.98% | -26.50% | -31.88% | -23.85% |
| EPS Basic | -30.62% | -27.23% | -25.50% | -25.83% | -12.21% |
| Normalized Basic EPS | -28.78% | -27.02% | -25.28% | -25.61% | -12.64% |
| EPS Diluted | -30.62% | -26.97% | -25.13% | -25.46% | -11.88% |
| Normalized Diluted EPS | -28.78% | -27.02% | -25.28% | -25.61% | -12.64% |
| Average Basic Shares Outstanding | -0.37% | -0.99% | -0.73% | -0.45% | -0.23% |
| Average Diluted Shares Outstanding | -0.37% | -0.99% | -0.73% | -0.45% | -0.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |